Age-related Macular Degeneration: Global summary from the VLEG study
The age-standardised prevalence of blindness due to age-related macular degeneration (AMD) declined by almost 30% from 1990 to 2020, which was likely associated with the widespread clinical introduction of anti-VEGF (vascular endothelial growth factor) therapy for exudative AMD.
Since most patients with AMD show the currently untreatable non-exudative form that can progress to atrophy of the foveal centre (geographic atrophy), the development of treatments and prophylactic measures specifically against non-exudative AMD are required.
It’s important to also note that for every person that experiences vision impairment and blindness from AMD, there are many more living with early stage AMD who need comprehensive and integrated people centred eye care services to prevent vision loss.
Adelson, J., Bourne, R., Briant, P., Flaxman, S., Taylor, H., Jonas, J., Abdoli, A., Abrha, W., Abualhasan, A., Abu-Gharbieh, E. and Adal, T. (2020). Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Global Health.